MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Ramiro Guerrero Purchases 78,239 Shares

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero acquired 78,239 shares of MAIA Biotechnology stock in a transaction that occurred on Thursday, August 27th. The stock was acquired at an average cost of $1.39 per share, with a total value of $108,752.21. Following the completion of the purchase, the director owned 689,081 shares in the company, valued at approximately $957,822.59. This represents a 12.81% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Ramiro Guerrero also recently made the following trade(s):

• On Friday, August 28th, Ramiro Guerrero acquired 46,620 shares of MAIA Biotechnology stock. The shares were acquired at an average price of $1.35 per share, with a total value of $62,937.00.
• On Wednesday, August 26th, Ramiro Guerrero bought 8,931 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $1.39 per share, for a total transaction of $12,414.09.
• On Monday, August 24th, Ramiro Guerrero bought 1,794 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $1.33 per share, for a total transaction of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero purchased 11,899 shares of MAIA Biotechnology stock. The stock was bought at an average cost of $1.37 per share, with a total value of $16,301.63.

MAIA Biotechnology Stock Performance

Shares of NYSEAMERICAN MAIA traded down $0.01 during mid-day trading on Tuesday, reaching $1.30. The company had a trading volume of 304,095 shares, compared to its average volume of 791,682. The company has a market capitalization of $79.08 million, a price-to-earnings ratio of -2.10 and a beta of 0.24. The stock has a fifty day moving average of $1.37 and a two-hundred day moving average of $1.44. MAIA Biotechnology, Inc. has a 12-month low of $0.87 and a 12-month high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Sell-side analysts forecast that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MAIA Biotechnology

Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its holdings in shares of MAIA Biotechnology by 3.6% during the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after acquiring an additional 7,746 shares in the last quarter. Marshall Wace LLP acquired a new position in MAIA Biotechnology in the 2nd quarter worth about $29,000. Jane Street Group LLC acquired a new position in MAIA Biotechnology in the 2nd quarter worth about $52,000. Centric Wealth Management raised its stake in shares of MAIA Biotechnology by 2.0% during the 4th quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock worth $897,000 after purchasing an additional 11,500 shares in the last quarter. Finally, Corsair Capital Management L.P. purchased a new stake in shares of MAIA Biotechnology during the 1st quarter worth about $140,000. 5.65% of the stock is owned by institutional investors and hedge funds.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical?stage biopharmaceutical company developing a proprietary platform for site?specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody?based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high?contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody?radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.